HighTower Advisors
HRMY icon

HighTower Advisors’s Harmony Biosciences HRMY Stock Holding History

HighTower Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Sell
11,924
-1,399
-11% -$44.1K ﹤0.01% 2871
2026
Q1 		$373K Buy
13,323
+3,866
+41% +$127K ﹤0.01% 2971
2025
Q4 		$354K Buy
9,457
+189
+2% +$6.21K ﹤0.01% 2912
2025
Q3 		$255K Buy
+9,268
New +$319K ﹤0.01% 3176
2025
Q2 		– Sell
-19,748
Closed -$655K – 3855
2025
Q1 		$655K Buy
19,748
+8,347
+73% +$299K ﹤0.01% 2257
2024
Q4 		$392K Sell
11,401
-68,560
-86% -$2.36M ﹤0.01% 2674
2024
Q3 		$3.2M Buy
79,961
+62,729
+364% +$2.2M ﹤0.01% 1244
2024
Q2 		$522K Buy
17,232
+1,947
+13% +$58.5K ﹤0.01% 2291
2024
Q1 		$511K Buy
15,285
+4,161
+37% +$134K ﹤0.01% 2271
2023
Q4 		$366K Sell
11,124
-84
-0.7% -$2.35K ﹤0.01% 2562
2023
Q3 		$370K Buy
+11,208
New +$389K ﹤0.01% 2435

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's HRMY Position: Q2 2026 in Review

HighTower Advisors reduced its Harmony Biosciences (HRMY) stake by 11% in Q2 2026, selling an estimated $44.1K and leaving 11,924 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #2871.

HighTower Advisors first reported a position in HRMY in Q3 2023 and has held it in 11 quarters since. The position peaked at $3.2M in Q3 2024. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • HighTower Advisors held 11,924 shares of Harmony Biosciences worth $434K as of Q2 2026.
  • HighTower Advisors sold 1,399 Harmony Biosciences shares in Q2 2026, an estimated $44.1K.
  • Harmony Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2871 holding.
  • HighTower Advisors first reported a position in Harmony Biosciences in Q3 2023 and has held it in 11 quarters since.
  • HighTower Advisors's Harmony Biosciences position peaked at $3.2M in Q3 2024.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.